Zacks Investment Research upgraded shares of Flexion Therapeutics (NASDAQ:FLXN) from a hold rating to a buy rating in a research note issued to investors on Saturday, Zacks.com reports. The brokerage currently has $12.00 price target on the specialty pharmaceutical company’s stock.

According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. “

A number of other research firms have also recently commented on FLXN. Northland Securities reissued a buy rating and set a $20.00 target price on shares of Flexion Therapeutics in a research report on Thursday, May 9th. Benchmark raised shares of Flexion Therapeutics from a hold rating to a buy rating and set a $19.00 target price for the company in a research report on Thursday, May 9th. ValuEngine raised shares of Flexion Therapeutics from a sell rating to a hold rating in a research report on Thursday, May 23rd. Finally, BidaskClub raised shares of Flexion Therapeutics from a strong sell rating to a sell rating in a research report on Saturday. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $23.57.

NASDAQ:FLXN opened at $11.92 on Friday. Flexion Therapeutics has a 52 week low of $8.76 and a 52 week high of $24.10. The company’s 50 day moving average price is $10.73. The company has a debt-to-equity ratio of 3.95, a current ratio of 7.80 and a quick ratio of 7.33. The stock has a market capitalization of $426.79 million, a PE ratio of -2.65 and a beta of 1.37.

Flexion Therapeutics (NASDAQ:FLXN) last posted its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.96) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.06) by $0.10. Flexion Therapeutics had a negative net margin of 368.31% and a negative return on equity of 175.29%. The company had revenue of $16.95 million during the quarter, compared to analysts’ expectations of $14.03 million. On average, equities analysts anticipate that Flexion Therapeutics will post -3.99 earnings per share for the current fiscal year.

In related news, Director C Ann Merrifield purchased 8,000 shares of the firm’s stock in a transaction on Thursday, May 23rd. The stock was acquired at an average price of $12.64 per share, with a total value of $101,120.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at approximately $126,400. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Michael D. Clayman purchased 2,317 shares of the firm’s stock in a transaction on Thursday, August 8th. The stock was bought at an average cost of $10.85 per share, with a total value of $25,139.45. Following the acquisition, the insider now owns 72,249 shares of the company’s stock, valued at approximately $783,901.65. The disclosure for this purchase can be found here. Insiders have purchased 14,817 shares of company stock valued at $175,364 in the last three months. 16.01% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Northern Trust Corp raised its holdings in shares of Flexion Therapeutics by 0.3% in the second quarter. Northern Trust Corp now owns 448,993 shares of the specialty pharmaceutical company’s stock worth $5,522,000 after buying an additional 1,529 shares during the last quarter. Macquarie Group Ltd. raised its holdings in shares of Flexion Therapeutics by 2.7% in the fourth quarter. Macquarie Group Ltd. now owns 68,484 shares of the specialty pharmaceutical company’s stock worth $775,000 after buying an additional 1,781 shares during the last quarter. Quantamental Technologies LLC raised its holdings in shares of Flexion Therapeutics by 310.1% in the second quarter. Quantamental Technologies LLC now owns 3,449 shares of the specialty pharmaceutical company’s stock worth $42,000 after buying an additional 2,608 shares during the last quarter. DekaBank Deutsche Girozentrale raised its holdings in shares of Flexion Therapeutics by 22.4% in the first quarter. DekaBank Deutsche Girozentrale now owns 15,300 shares of the specialty pharmaceutical company’s stock worth $343,000 after buying an additional 2,800 shares during the last quarter. Finally, American Century Companies Inc. raised its holdings in shares of Flexion Therapeutics by 2.1% in the fourth quarter. American Century Companies Inc. now owns 175,780 shares of the specialty pharmaceutical company’s stock worth $1,990,000 after buying an additional 3,666 shares during the last quarter. 89.12% of the stock is owned by institutional investors and hedge funds.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Further Reading: Discount Rate

Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.